Sci Data May 2023 PMID 37160957

Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer's Disease.

Caroline M Watson, Eric B Dammer, Lingyan Ping, Duc M Duong, Erica Modeste, E Kathleen Carter, Erik C B Johnson, Allan I Levey, James J Lah, Blaine R Roberts, Nicholas T Seyfried

Download social card

Mentions

Peak: 4 in May 2023

across 2 sources since May 2023

Extended reach

11,640

potential audience

Total likes

Video views

Mentions per month

May 2023 – Aug 2023

Where it's discussed

X / Twitter4 posts
YouTube1 videos

AI synopsis

What people are saying

The group demonstrates strong interest by discussing specific biomarkers such as SMOC1 and VGF, using terminology that reflects an understanding of their relevance. The tone indicates appreciation for the method’s potential to impact diagnosis, as seen in phrases like 'distinguish disease stages' and 'reliable tool for monitoring.' Engagement is moderate, with some sharing insights into protein roles and implications for future research, reflecting both curiosity and recognition of the study's significance.

AgreementModerate agreement

Most discussions recognize the significance of the research, especially regarding its ability to distinguish between different disease stages and its potential for improving diagnosis.

InterestHigh interest

The detailed mentions of specific proteins and implications for Alzheimer's diagnosis indicate high curiosity and engagement with the scientific content.

EngagementModerate engagement

Participants actively highlight particular proteins like SMOC1, GDA, VGF, and NPTX2, and discuss the method's reliability, showing meaningful interaction.

ImpactModerate impact

The emphasis on the method's potential to enhance diagnostic accuracy suggests that users see this as an important advancement in Alzheimer's research.

Abstract in brief

The study developed a sensitive mass spectrometry method to quantify cerebrospinal fluid proteins that serve as biomarkers for Alzheimer's disease (AD), helping to distinguish between different stages and diagnostic categories.
Researchers identified specific proteins involved in AD pathology and neurodegeneration, such as SMOC1, GDA, proteins related to glycolysis, and neuronal proteins like VGF and NPTX2, to differentiate between various patient groups.
The method showed consistent accuracy with low variability across samples, demonstrating its potential as a reliable tool for monitoring AD progression and improving diagnosis beyond traditional amyloid and Tau markers.

Read the full abstract

All mentions

Quantitative Analysis of CSF Protein Biomarkers for Alzheimer's Disease

This study developed a sensitive mass spectrometry method to quantify cerebrospinal fluid proteins as biomarkers for Alzheimer’s disease, providing insights into disease stages and neurodegeneration with high accuracy…

STEM RTCL TV · Aug 23, 2023 65 views

GuitarPlayer5150

@GPlayer5150 · X

RT @mlperk1: @CuecaLabs @DlakaDarko @GPlayer5150 @mega_pindang71 @JCPEREZCODEX @Jikkyleaks Learning... https://t.co/Un4C6HxQwJ Proteins th…

May 13, 2023 · 1 share · 741 followers View post →

Meri Perkins

@mlperk1 · X

May 13, 2023 · 1 like · 1 share · 1,295 followers View post →

Your HPLC DataBase

@LC_Analysis · X

Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer’s Disease https://t.co/vUKiZ7ms98

May 10, 2023 · 2 likes · 3,545 followers View post →

BioMassSpec

@realBioMassSpec · X

Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer’s Disease #SciData https://t.co/Q0RCSItVXG

May 10, 2023 · 3 likes · 5,991 followers View post →